NCT07535359
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07535359
Title Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
Recruitment No longer available
Gender both
Phase Expanded access
Variant Requirements No
Sponsors Daiichi Sankyo
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Health Partners Oncology Saint Paul Minnesota 55101 United States Details
Citizens Memorial Hospital Bolivar Missouri 65613 United States Details
Duke Cancer Institute Durham North Carolina 27710 United States Details
Baptist Cancer Center Memphis Tennessee 38120 United States Details
University of Texas Southwestern Medical Dallas Texas 75390 United States Details
Huntsman Cancer Institute & Hospital Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field